Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737940 · ClinicalTrials.gov registry record · Phase 2
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT05737940 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 260 participants.
The verdict
NCT05737940, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Interventions
- DRUG Placebo
- DRUG AZD3427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05737940
The ClinicalTrials.gov registry entry for NCT05737940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05737940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05737940 about?
NCT05737940 is a clinical study titled "A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2". This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
What is the current status of trial NCT05737940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2023-04-24. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT05737940?
The interventions under investigation include: Placebo (DRUG), AZD3427 (DRUG).
Who is sponsoring clinical trial NCT05737940?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.